User Fee Workload Decline Leads To Staff Decreases In Regulatory Affairs
This article was originally published in The Tan Sheet
Executive Summary
FDA's Office of Regulatory Affairs will reduce its Prescription Drug User Fee Act II-funded staff by 40 full-time equivalents for each of the remaining two years of the act's authorization period. The plan calls for 10 fewer FTEs in fiscal 1999, and for 40 fewer FTEs in each subsequent year through 2002.
You may also be interested in...
User Fee Revision Reduces Expected CDER Staffing Increases By 60%
A revision of FDA's estimated revenues from user fees will reduce the expected additions in staff to the Center for Drug Evaluation & Research to 40% of previous estimates.
FDA Drug-Drug Interaction Database Will Be Functional By 2000, Plan Says
FDA's drug-drug interaction scientific database will be functional two years ahead of schedule in the Center for Drug Evaluation & Research, according to FDA's revised Prescription Drug User Fee Act information management plan issued Aug. 27.
FDA Mutual Recognition Implementation Will Cost $10 Mil. -GAO Report
FDA plans to spend $10 mil. to implement the mutual recognition agreement plan for the assessment of equivalency of Good Manufacturing Practices of European Union member states and companies.